Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 2
Submit an article Journal homepage
41
Views
9
CrossRef citations to date
0
Altmetric
Review

Global dissemination of β2-lactamases mediating resistance to cephalosporins and carbapenems

Thomas D Gootz Pfizer Global Research and Development, Department of Antimicrobials, Immunology and Cancer, Eastern Point Road, Groton, Connecticut 06340, USA. [email protected]
Pages 317-327 | Published online: 10 Jan 2014

References

  • Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for 13-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39,1211–1233 (1995).
  • •Functional classification scheme.
  • Livermore DM. B-lactamases in laboratory and clinical resistance. Clin. Microbial Rev. 8,557–584 (1995).
  • Medeiros AA. Evolution and dissemination of B-lactamases accelerated by generations of B-lactam antibiotics. Clin. Infect. Dis. 24\(Suppl. 1), S19—S45 (1997).
  • Bradford PA. Extended-spectrum 13-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin. Microbial. Revs. 14,933–951 (2001).
  • ••Excellent review of ESPLs.
  • Philippon, A, Arlet, G, Jacoby, GA. Plasmid-determined ampC-type 13-lactamases. Antimicrob. Agents Chemother. 46,1–11 (2002).
  • •• Excellent reference for plasmid-encoded ampC genes.
  • Richmond MH, Sykes RB. The 13-lactamases of Gram-negative bacteria and their possible physiological role. Adv. Microb. Physiol. 9,31–88 (1973).
  • Ambler RP. The structure of 13-lactamases. Phil. Trans. R. Soc. Land. Biol. 289,321–331 (1980).
  • ••Classic Ambler scheme paper.
  • Bush K. New B-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32,1085–1089 (2001).
  • Knox JR. Extended-spectrum and inhibitor-resistant TEM-type 13-lactamases: mutations, specificity and three-dimensional structure. Antimicrob. Agents Chemother. 39,2593–2601 (1995).
  • Massova I, Mobashery S. Molecular basis for interactions between B-lactam antibitotics and B-lactamases. Acc. Chem. Res. 30,162–168 (1997).
  • Bulchey A, Massova I, Miyashita K, Mobashery S. Nuances of mechanisms and their implications for evolution of the versatile B-lactamase activity: from biosynthetic enzymes to drug resistance factors. J. Am. Chem. Soc. 119, 7619–7625 (1997).
  • Maveyraud L, Mourey L, Kotra L, et al. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A 13-lactamases from antibiotic-resistant bacteria. J. Am. Chem. Soc. 120, 9748–9752 (1998).
  • •• Excellent paper describing the catalysis of carbapenems at the active site of TEM.
  • Taibi-Tronche P, Massova I, Vakulenko S, Lerner SA, Mobashery S. Evidence for structural elasticity of class A 13-lactamases in the course of catalytic turnover of the novel cephalosporin cefepime. J. Am. Chem. Soc. 118, 7441–7448 (1996).
  • Nukaga M, Mayama K, Crichlow GV, Knox JR. Structure of an extended-spectrum class A B-lactamase from Proteus vulgaris Kl. Mal Biol. 317, 109–117 (2002).
  • Rasmussen BA, Bush K. Carbapenem-hydrolyzing B-lactamases. Antimicrob. Agents Chemother. 41,223–232 (1997).
  • Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbial Infect. 8, 321–331 (2002).
  • Pottumarthy S, Smith Moland E, Juretschko S, Swanzy SR, Thomson KS, Fritsche, TR. NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emer. Infect. Dis. 9,999–1002 (2003).
  • Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing 13-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45, 1151–1161 (2001).
  • Majiduddin FK, Palzkill T Amino acid sequence requirements at residues 69 and 238 for the SME-1 B-lactamase to confer resistance to B-lactam antibiotics. Antimicrob. Agents Chemother. 47, 1062–1067 (2003).
  • Hernandez-Alles S, Alberti S, Alvarez D, et al. Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 145,673–679 (1999).
  • ••Excellent source paper for porins ofK pneumoniae.
  • Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM.Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47, 1297–1300 (2003).
  • Lartigue MF, Leflon-Guibout V, Poirel L, Nordmann P, Nicolas-Chanoine M-H. Promoters P3, Pa/Pb, P4 and P3 upstream from b/aTEm genes and their relationship to B-lactam resistance. Antimicrob. Agents Chemother. 46, 4035–4037 (2002).
  • Livermore DM. Acquired carbapenemases. J. Antimicrob. Chemother. 39, 673–676 (1997).
  • Hirakata Y, Yamaguchi T, Nakano M, et al. Clinical and bacteriological characteristics of IMP-type metallo-B-lactamase-producing Pseudomonas aeruginosa. Clin. Infect. Dis. 37, 26–32 (2003).
  • Yum JH, Yi K, Lee H, et al. Molecular characterization of metallo-B-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the b/avim2 gene cassettes. J. Antimicrob. Chemother. 49, 837–840 (2002).
  • Yan J-J, Ko W-C, Chuang C-L, Wu J-J. Metallo-B-lactamase-producing enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J. Antimicrob. Chemother. 50, 503–511 (2002).
  • Pallecchi L, Ricci° ML, Docquier J-D, Fontana R, Rossolini GM. Molecular heterogeneity of b/awm_2-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-B-lactamase. FEMS Microbial. Lett. 195, 145–150 (2001).
  • Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr. Opin. Microbial. 3, 489–495 (2000).
  • Beadle BM, Shoichet BK. Structural basis for imipenem inhibition of class C B-lactamases. Antimicrob. Agents Chemother. 46, 3978–3980 (2002).
  • Vakulenko SB, Golemi D, Geryk B, et al Mutational replacement of leu-293 in the class C Enterobacter cloacae P99 B-lactamase confers increased MIC of cefepime. Antimicrob. Agents Chemother. 46, 1966–1970 (2002).
  • ••Interesting paper demonstrating the effectof a single amino acid replacement on substrate utilization.
  • Crichlow GV, Nukaga M, Doppalapudi VR, Buynak FD, Knox JR. Inhibition of class C B-lactamases: structure of a reaction intermediate with a cephem sulfone. Biochemistry 40, 6233–6239 (2001).
  • Hanson ND, Sanders CC. Regulation of inducible ampC B-lactamase expression among enterobacteriaceae. Curr. Pharm. Design. 5, 881–894 (1999).
  • ••Good review of bla gene regulation.
  • Siu LK, Lu P-L, Chen J-Y, Lin FM, Chang S-C. High-level expression of ampC B-lactamase due to insertion of nucleotides between-10 and-35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum cephalosporin treatment. Antimicrob. Agents Chemother. 47, 2138–2144 (2003).
  • Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48, 15–22 (2004).
  • Thomson KS, Smith Moland E. Version 2000: the new B-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect. 2, 1225–1235 (2000).
  • Afzal-Shah M, Woodford N, Livermore DM. Characterization of oxa-25, oxa-26 and oxa-27, molecular class D B-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 45, 583–588 (2001).
  • Golemi D, Maveyraud L, Vakulenko S, et al. The first structural and mechanistic insights for class D B-lactamases: evidence for a novel catalytic process for turnover of B-lactam antibiotics. J. Am. Chem. Soc. 122, 6132–6133 (2000).
  • Maveyraud L, Golemi-Kotra D, Ishiwata A, Meroueh O, Mobashery S, Samama J-P. High-resolution x-ray structure of an acyl-enzyme species for the class D oxa-10 B-lactamase. J. Am. Chem. Soc. 124, 2461–2465 (2002).
  • Poirel L, Girlich T, Nordman B Oxa-28, an extended-spectrum variant of oxa-10 B-lactamase from Pseudomonas aeruginosa and its plasmid-and integron-located gene. Antimicrob. Agents Chemother. 45, 447–453 (2001).
  • Philippon LN, Naas T, Bouthors AT, et al Oxa-18, a class D davulanic acid-inhibited extended-spectrum B-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41, 2188–2195 (1997).
  • Daniel F, Hall LM, Livermore DM. Laboratory mutants of oxa-10 B-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 43, 339–344 (1999).
  • Livermore DM. Bacterial resistance: origins, epidemiology and impact. Clin. Infect. Dis. 36\(Suppl. 1), S11—S23 (2003).
  • Thomson KS, Sanders CC, Smith Moland E. Use of microdilution panels with and without B-lactamase inhibitors as a phenotypic test for B-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii and Serratia marcescens. Antimicrob. Agents Chemother. 43, 1393–1400 (1999).
  • Perilli M, Sgatore B, De Massis MR, et al. TEM-72, a new extended-spectrum B-lactamase detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrob. Agents Chemother. 44, 2537–2539 (2000).
  • Hujer AM, Hujer KM, Helfand MS, Anderson VE, Bonomo RA. Amino acid substitutions at ambler position gly238 in the SHV-1 B-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins. Antimicrob. Agents Chemother. 46, 3971–3977 (2002).
  • Majiduddin FK, Palzkill T An analysis of why highly similar enzymes evolve differently. Genetics 163, 457–466 (2003).
  • ••Excellent paper describing the directionsof mutation in two related proteins.
  • Huletsky AJ, Knox JR, Levesque RC. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type B-lactamase probed by site-directed mutagenesis and three-dimensional modeling. J. Biol. Chem. 268, 3690–3697 (1993).
  • Wang X, Minasov G, Shoichet BK. The structural bases of antibiotic resistance in the clinically derived mutant B-lactamases TEM-30, TEM-32 and TEM-34. J. Bial Chem. 277, 32149–32156 (2002).
  • ••Good example of the evolution ofESBLs.
  • National Committee for Clinical Laboratory Standards, Performance standards for susceptibility testing; 14th Informational Supplement M100-514, 24, 1. National Committee for Clinical Laboratory Standards, PA, USA (2004).
  • Thomson KS. Controversies about ESBL and AmpC B-lactamases. Emerg. Infect. Dis. 7(2), 333–336 (2001).
  • Aumeran C, Chanal C, Labia R, Sirot D, Sirot J, Bonnet R. Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum B-lactamase CTX-M-9. Antimicrob. Agents Chemother. 47, 2958–2961 (2003).
  • Winokur PL, Canton R, Casellas J-M, Legakis N. Variations in prevalence of strains expressing an extended-spectrum 0-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clin. Infect. Dis. 32\(Suppl. 2), S94—S103 (2001).
  • Goossens H, MYSTIC study group Europe. MYSTIC program: summary of European data from 1997 to 2000. Diag. Microbial. Infect. Dis. 41,183–189 (2001).
  • Mathai D, Todd Lewis M, Kugler KC, Pfaller MA, Jones RN. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I-results from the SENTRY antimicrobial surveillance program (North America, 1998). Diag. Microbial. Infect. Dis. 39, 105–116 (2001).
  • Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended-spectrum B-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY antimicrobial surveillance program (1998-1999). Diag. Microbial. Infect. Dis. 42,193–198 (2002).
  • Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diag. Microbial. Infect. Dis. 44,273–280 (2003).
  • Neuhauser, MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA 289,885–888 (2003).
  • Smith Moland E, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson K. Occurrence of newer B-lactamases in Klebsiella pneumoniae isolates from 24 US hospitals. Antimicrob. Agents Chemother. 46,3837–3842 (2002).
  • Quale JM, Landman D, Bradford PA, et al. Molecular epidemiology of a citywide outbreak of extended-spectrum B-lactamase-producing Klebsiella pneumoniae infection. Clin. Infect. Dis. 35,834–841 (2002).
  • ••Nice example of il-lactamaseidentification in outbreak strains.
  • Nathisuwan S, Burgess D, Lewis JS 2nd. Extended-spectrum B-lactamases: epidemiology, detection and treatment. Pharmacotherapy 21,920–928 (2001).
  • Tenover FC, Mohanned MJ, Gorton TS, Dembek ZF. Detection and reporting of organisms producing extended-spectrum 0-lactamase: survey of laboratories in Connecticut. J. Clin. Microbial. 37, 4065–4070 (1999).
  • Tenover FC, Raney PM, Williams PP, et al. Evaluation of the NCCLS extended-spectrum B-lactamase confirmation methods for Escherichia coli with isolates collected during project ICARE. J. Clin. Microbial. 41,3142–3146 (2003).
  • Rasheed JK, Anderson GJ, Yigit H, et al. Characterization of the extended-spectrum B-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob. Agents Chemother. 44,2382–2388 (2000).
  • Jacoby GA, Sutton L. Properties of plasmids responsible for production of extended-spectrum B-lactamases. Antimicrob. Agents Chemother. 35, 164–169 (1991).
  • Burgess DSRG 2nd, Lewis JS 2nd, Jorgensen JH, Patterson JE, Hall. Clinical and microbiologic analysis of a hospital's extended-spectrum B-lactamase-producing-isolates over a 2-year period. Pharmacotherapy 23,1232–1237 (2003).
  • Rodriguez-Bano J, Navarro D, Martinez-Martinez L, et al. Clinical epidemiology of extended-spectrum B-lactamase producing enterobacteriaceae in the community. 42nd Interscience Conf Antimicrobial Agents Chemother (2002) (Abstract C2–1880).
  • Doi Y, Shibata N, Shibayama K, et al. Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 46,2427–2434 (2002).
  • Queenan A-M, Jenkins S, Bush K. Cloning and biochemical characterization of FOX-5, an ampC-type plasmid-encoded B-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob. Agents Chemother. 45, 3189–3194 (2001).
  • ••Good example of both genetic andbiochemical characterization of a specific il-lacamase.
  • Rottman M, Benzerara Y, Hanau-Bercot B, Bizet C, Philippon A, Arlet G. Chromosomal ampC genes in Enterobacter species other than Enterobacter cloacae and ancestral association of the ACT-1 plasmid-encoded cephalosporinase to Enterobacter asburiae. FEMS Microbial. Lett. 210, 87–92 (2002).
  • Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumaniae is associated with the combination of ACT-1, a plasmid-mediated ampC B-lactamase and the loss of an outer membrane porin. Antimicrob. Agents Chemother. 41,563–569 (1997).
  • Reisbig MD, Hossain A, Hanson N. Factors influencing gene expression and resistance for Gram-negative organisms expressing plasmid-encoded ampC genes of Enterobacter origin. J. Antimicrob. Chemother. 51,1141–1151 (2003).
  • Fortineau N, Poirel L, Nordmann R Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. J. Antimicrob. Chemother. 47, 207–210 (2001).
  • Craig NIL, Craigie R, Gellert M and Lanbowitz AM (Eds), ASM Press, DC, USA 162–173 (2002).
  • Martinez-Martinez L, Pascual A, Hernandez-Alles S, et al. Roles of B-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43,1669–1673 (1999).
  • Yigit H, Anderson GJ, Biddle JW, et al. Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of ompF and ompC porin analogs. Antimicrob. Agents Chemother. 46,3817–3822 (2002).
  • Coudron PE, Hanson ND, Climo MW Occurrence of extended-spectrum and ampC B-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 ampC B-lactamases. J. Clin. Microbial. 41, 772–777 (2003).
  • Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of plasmid-mediated ampC B-lactamases in the United States. Antimicrob. Agents Chemother. 47, (2004) (In Press).
  • Odeh R, Kelkar S, Hujer AM, Bonomo RA, Schreckenberger PC, Quinn JP. Broad resistance due to plasmid-mediated ampC B-lactamases in clinical isolates of Escherichia coli. Clin. Infect. Dis. 35, 140–145 (2002).
  • Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 21,455–458 (2000).
  • Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32, 1162–1171 (2001).
  • Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280, 1233–1237 (1998).
  • Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, 13-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 21, 583–592 (2001).

Websites

  • Bush K, Jacoby G. Amino acid sequences for TEM, SHY and OXA extended-spectrum and inhibitor resistant 11-lactamases. Lahey clinic website (Accessed March 2004). www.lahey.org/studies/webt.htm

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.